Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GreKo III enzalutamide study in advanced or metastatic ovarian granulosa cell tumors
2015-004469-10Phase 2Terminated
- Sponsor
- Grupo Español de Tumores Huérfanos e Infrecuentes
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in ovarian granulosa cell tumor (OGCT), sponsored by Grupo Español de Tumores Huérfanos e Infrecuentes. Primary endpoint: Overall response rate. Started Dec 2017; status: terminated.
02
Drugs
enzalutamide
03
Conditions
ovarian granulosa cell tumor (OGCT)
Beyond the preview
Go deeper on 2015-004469-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004469-10.